^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Vulvar Cancer

    1d
    DOSTCONICG: The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Cukurova University
    New trial
    2d
    [177Lu]Lu-AKIR001 First-in-human Study (clinicaltrials.gov)
    P1, N=15, Recruiting, Karolinska University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF wild-type
    3d
    A Prospective Single-Arm Exploratory Study on CT-Based Radiomics Combined with Clinical Parameters for Predicting Lymph Node Metastasis in Gynecological Malignancies (Cervical, Ovarian, Endometrial and Vulval Cancers) (ChiCTR2500113585)
    P=N/A, N=350, Not yet recruiting, The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University
    New trial
    3d
    A cohort study on the impact of modified open three-incision surgical approach on survival prognosis of vulvar cancer (ChiCTR2500113300)
    P=N/A, N=502, Completed, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New trial
    6d
    Malignant vascular neoplasms of the distal female genital tract: a series of 19 cases emphasizing unusual features and diagnostic challenges. (PubMed, Histopathology)
    While many morphologic features of vascular lesions at this site are shared with those of extra-genital soft tissues, pathologists must be aware that these tumours may occur in the vulvovaginal area and display unconventional clinical profiles. As such, a broad differential for epithelioid and spindle cell neoplasms at this site is prudent.
    Journal
    |
    CAMTA1 (Calmodulin Binding Transcription Activator 1)
    6d
    e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=23, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    11d
    Diagnostic Performance of the ASCL1/ZNF582 Methylation Test for Detection of High-Grade Vulvar Intraepithelial Neoplasia and Vulvar Cancer. (PubMed, Mol Diagn Ther)
    In conclusion, the ASCL1/ZNF582 methylation assay accurately detects high-grade VIN and vulvar cancer, while minimizing the detection of benign and low-grade lesions, indicating its clinical value.
    Journal
    |
    MIR24-2 (MicroRNA 24-2) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • MIR124-2 (MicroRNA 124-2)
    |
    PreCursor-M AnoGYN Methylation Assay
    13d
    Vulvar dermatofibrosarcoma protuberans in a 55-year-old female: A case report, surgical reconstruction approach and literature review. (PubMed, Gynecol Oncol Rep)
    Single-stage radical excision with immediate reconstruction can achieve favorable oncologic and functional outcomes in vulvar DFSP. Long-term surveillance remains essential due to the potential for late local recurrence.
    Journal
    |
    CD34 (CD34 molecule)
    13d
    Management of Bartholin's Gland Carcinoma in a Perimenopausal Woman: A Case Report. (PubMed, Am J Case Rep)
    CASE REPORT Treatment included surgical removal of the tumor, followed by chemotherapy with paclitaxel and carboplatin and adjuvant radiotherapy. CEA and CA 19-9 may serve as useful markers of treatment response and cancer remission. Genomic or RNA sequencing and HPV genotyping of tumor samples are advisable, given the absence of a well-defined molecular profile for Bartholin's gland carcinoma.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    |
    carboplatin • paclitaxel
    14d
    Transcriptomics driven identification of hub gene miRNA interactions for biomarker and therapeutic target discovery in gynecological cancers. (PubMed, Front Oncol)
    The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • BIRC5 (Baculoviral IAP repeat containing 5) • AURKA (Aurora kinase A) • TGFB1 (Transforming Growth Factor Beta 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • KIF11 (Kinesin Family Member 11) • MIR381 (MicroRNA 381) • MIR495 (MicroRNA 495) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) • CCNB1 (Cyclin B1) • CDCA8 (Cell Division Cycle Associated 8) • MIR653 (MicroRNA 653)
    15d
    GATA3 Is Underexpressed in Penile Neoplasia: Potential Implications in Diagnosis and Pathogenesis. (PubMed, Am J Surg Pathol)
    HPV-associated PSCC had a more severe loss (91%) than HPV-associated PeIN (39%) (P=0.008). These findings suggest that GATA3 alterations may be an early event during tumorigenesis, and that this marker may represent a useful complement to p16 and p53 in the differential diagnosis of HPV-independent PeIN from benign mimickers.
    Journal
    |
    GATA3 (GATA binding protein 3)
    19d
    Cancer Loyalty Card Study 2 (CLOCS-2) (clinicaltrials.gov)
    P=N/A, N=2900, Recruiting, Imperial College London | N=1500 --> 2900 | Trial primary completion date: Apr 2026 --> Feb 2027
    Enrollment change • Trial primary completion date